Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
16.67
-0.86 (-4.91%)
Feb 20, 2026, 3:46 PM EST - Market open
Corvus Pharmaceuticals Employees
Corvus Pharmaceuticals had 31 employees as of December 31, 2024. The number of employees increased by 3 or 10.71% compared to the previous year.
Employees
31
Change (1Y)
3
Growth (1Y)
10.71%
Revenue / Employee
n/a
Profits / Employee
-$486,290
Market Cap
1.40B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 31 | 3 | 10.71% | 31 | 0 |
| Dec 31, 2023 | 28 | -1 | -3.45% | 28 | 0 |
| Dec 31, 2022 | 29 | 1 | 3.57% | 29 | 0 |
| Dec 31, 2021 | 28 | -14 | -33.33% | 28 | 0 |
| Dec 31, 2020 | 42 | -11 | -20.75% | 42 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ocular Therapeutix | 325 |
| Biohaven | 256 |
| uniQure | 209 |
| Relay Therapeutics | 188 |
| Celldex Therapeutics | 186 |
| Monte Rosa Therapeutics | 147 |
| AnaptysBio | 136 |
| Kodiak Sciences | 123 |
CRVS News
- 27 days ago - Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M - GlobeNewsWire
- 4 weeks ago - Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock - GlobeNewsWire
- 4 weeks ago - Corvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved Upon - Seeking Alpha
- 4 weeks ago - Soquelitinib Data Push Corvus Pharmaceuticals Stock Higher: What You Should Know - Seeking Alpha
- 4 weeks ago - Corvus Pharmaceuticals, Inc. (CRVS) Discusses Phase 1 Clinical Trial Results of Soquelitinib in Atopic Dermatitis with Focus on Cohort 4 Transcript - Seeking Alpha
- 4 weeks ago - Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 4 weeks ago - What made Corvus stock double on Tuesday and is it sustainable? - Invezz
- 4 weeks ago - Corvus Stock Spikes On Heels Of Strong Eczema Study Results - Benzinga